Tandem Diabetes Care Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Tandem Diabetes Care stock has a consensus rating of "Buy" and an average price target of $29.2. The average 1-year stock price forecast is 62.76% higher than the current stock price, while the lowest is $17 (-5.24%) and the highest is $50 (+178.71%).

Price Target: $29.2 (+62.76%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$17	$29.2	$27.5	$50
Change	-5.24%	+62.76%	+53.29%	+178.71%

Analyst Ratings

The average analyst rating for Tandem Diabetes Care stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	8	9	9	9	10
Buy	2	2	3	3	3	3
Hold	14	14	11	11	11	10
Sell	1	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	24	24	23	23	23	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Larry Biegelsen Wells Fargo	Wells Fargo	Buy Upgrades $21 → $27	Buy	Upgrades	$21 → $27	+50.50%	Jun 1, 2026
Joanne Wuensch Citi	Citi	Hold Maintains $22 → $17	Hold	Maintains	$22 → $17	-5.24%	May 28, 2026
David Roman Goldman Sachs	Goldman Sachs	Hold Maintains $24 → $21	Hold	Maintains	$24 → $21	+17.06%	May 27, 2026
Travis Steed Bank of America Securities	Bank of America Securities	Hold Maintains $35 → $25	Hold	Maintains	$35 → $25	+39.35%	May 18, 2026
Bruce Jackson Benchmark Co.	Benchmark Co.	Hold Initiates n/a	Hold	Initiates	n/a	n/a	May 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.07B

from 1.01B

5.80%

from 1.01B

Revenue Next Year

1.21B

from 1.07B

12.29%

from 1.07B

EPS This Year

-0.71

from -2.58

EPS Next Year

0.06

from -0.71

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	702.80M	801.22M	747.72M	940.20M	1.01B	1.07B
Revenue Growth	40.89%	14.00%	-6.68%	25.74%	7.93%	5.80%
Gross Profit	376.22M	412.99M	367.69M	489.57M	546.01M	607.40M
Gross Margin	53.53%	51.54%	49.17%	52.07%	53.81%	56.57%
Operating Income	22.65M	-61.81M	-140.38M	-99.13M	-78.12M	-45.16M
Net Income	15.57M	-94.59M	-222.61M	-96.03M	-204.71M	-47.44M
EPS	-	-	-	-	-2.58	-0.71
Free Cash Flow	55.93M	8.76M	-105.19M	33.35M	-44.73M	3.70M
No. Analysts	-	-	-	-	-	22

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.1B
Avg	1.1B
Low	1.1B

Revenue Growth

Revenue Growth	2026	2027	2028
High	6.5%
Avg	5.8%
Low	5.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.41
Avg	-0.71
Low	-1.02

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-